Amended Safety Assessment of PEG Propylene Glycol Esters As Used in Cosmetics
Total Page:16
File Type:pdf, Size:1020Kb
Amended Safety Assessment of PEG Propylene Glycol Esters as Used in Cosmetics Status: Draft Final Amended Report for Panel Review Release Date: November 11, 2016 Panel Meeting Date: December 5-6, 2016 The 2016 Cosmetic Ingredient Review Expert Panel members are: Chair, Wilma F. Bergfeld, M.D., F.A.C.P.; Donald V. Belsito, M.D.; Ronald A. Hill, Ph.D.; Curtis D. Klaassen, Ph.D.; Daniel C. Liebler, Ph.D.; James G. Marks, Jr., M.D.; Ronald C. Shank, Ph.D.; Thomas J. Slaga, Ph.D.; and Paul W. Snyder, D.V.M., Ph.D. The CIR Director is Lillian J. Gill, D.P.A. This report was prepared by Lillian C. Becker, Scientific Analyst/Writer. © Cosmetic Ingredient Review 1620 L Street, NW, Suite 1200 Washington, DC 20036-4702 ph 202.331.0651 fax 202.331.0088 [email protected] Commitment & Credibility since 1976 MEMORANDUM To: CIR Expert Panel and Liaisons From: Lillian C. Becker, M.S. Scientific Analyst and Writer Date: November 11, 2016 Subject: PEG Propylene Glycol Derivatives As Used In Cosmetics Attached is the Draft Final Amended Report of 7 PEG Propylene Glycol Derivatives as used in cosmetics. [pegpge122016rep] At the June 2016 meeting, the Panel reopened this safety assessment to remove the caveat that ingredients containing PEGs should not be used on damaged skin and there was a significant increase in the number of uses of PEG-25 Propylene Glycol Oleate. Additionally, because it is similar to the other ingredients in this group, the Panel added PEG Propylene Glycol Caprylate/Caprate to this safety assessment. The Panel concluded that these ingredients are safe as used in cosmetics. Council comments have been addressed. [pegpge122016PCPC_1,2] Because there is an ether (PEG-25 Propylene Glycol Stearate) included in this ingredient group, the Council suggested that the group name was not quite appropriate. Staff suggests that the name of this group be changed from “PEG Propylene Glycol Esters” to “PEG Propylene Glycol Derivatives”. The original report contained very little data on the ingredients. The Panel relied on other CIR reports on related ingredients, the moieties, and component parts of these ingredients for read across and information purposes. The Panel affirmed that this approach was appropriate for this group of ingredients. No new data were discovered in the literature and no additional toxicity data were submitted. The following reports are included in this packet: Original (2001) Safety Assessment [pegpge122016Prev_1] PEG Diesters (including PEG Distearates) [pegpge122016Prev_2] PEG Stearates [pegpge122016Prev_3] PEG Stearates (re-review summary) [pegpge122016Prev_4] PEGs [pegpge122016Prev_5] Propylene Glycol Esters [pegpge122016Prev_6] Oleic Acid and Stearic Acid [pegpge122016Prev7] Oleic Acid and Stearic Acid (re-review summary) [pegpge122016Prev8] To facilitate your review, relevant information from the original review is included throughout the text of the report (indicated by italics). The Panel is to decide if they are comfortable with the name change and, if not, decide on an appropriate name for this ingredient group. The Panel should also carefully review the Abstract, Discussion, and Conclusion of this report and issue a Final Amended Safety Assessment. __________________________________________________________________________________________ 1620 L Street, NW Suite 1200, Washington, DC 20036 (Main) 202-331-0651 (Fax) 202-331-0088 (Email) [email protected] (Website) www.cir-safety.org RE-REVIEW FLOW CHART INGREDIENT/FAMILY_____PEG Propylene Glycol Esters_________________________________ MEETING _______ Dec 2016__________________________________________________________ Public Comment CIR Expert Panel Re-Review Rpt Status New Data; or announce 15 years OR request since last review Re-review to Panel PRIORITY LIST June 2016 Are new data cause to reopen? YES One proposed NO add -on. DRAFT AMENDED DAR REPORT* Are new ingredients appropriate for inclusion/re-open? Table Table IDA TAR No Yes IDA Notice IDA RE-REVIEW Admin Book SUMMARY DRAFT TENTATIVE Draft TAR AMENDED REPORT 60 day public comment period Table Table Tentative Amended Report June 13, 2016 Issue TAR Draft FAR DRAFT FINAL AMENDED 60 day Public comment period REPORT Dec 2016 Table Table Different Conclusion Final Amended Issue PUBLISH Report FAR Distributed for comment only -- do not cite or quote *If Draft Amended Report (DAR) is available, the Panel may choose to review; if not, CIR staff prepares DAR for Panel Review. Distributed for comment only -- do not cite or quote Report History of PEG Propylene Glycol Derivatives 2001 – The safety assessment of 6 PEG Propylene Glycol Esters is published with a conclusion of safe as used. June, 2016 – Re-review. The Panel reopened to add PEG-6 Propylene Glycol Caprylate/Caprate and to remove the caveat that ingredients containing PEGs should not be used on damaged skin. There was a significant increase in the number of uses of PEG-25 Propylene Glycol Oleate. There is no new data available for these ingredients. The original safety assessment relied on the safety of related and component ingredients. The Panel found this to be an acceptable approach for the re-review and the additional ingredient. The reports on the related and component ingredients have been re-reviewed since the original report. The Panel concluded that these ingredients are safe as used. December, 2016 – The name of the report is potentially changed from “PEG Propylene Glycol Esters” to “PEG Propylene Glycol Derivatives” because the group contains an ester. The Panel is to review the report, in particular the Abstract, Discussion, and Conclusion, and issue a Final Report. Distributed for comment only -- do not cite or quote PEG Propylene Glycol Derivatives Data Profile for December, 2016. Writer – Lill Becker Acute Repeated ADME toxicity dose toxicity Irritation Sensitization Use Log K Penetration Dermal Oral Dermal Inhale Oral Dermal Ocular Ocular In Dermal Dermal Dermal In Vitro Animal Human Vitro In Repro/Devel Genotoxicity Carcinogenicity Phototoxicity Inhale ow Animal Human Animal Vitro PEG-25 Propylene Glycol O O O O O O Stearate N PEG-75 Propylene Glycol Stearate PEG-120 Propylene Glycol Stearate PEG-10 Propylene Glycol PEG-8 Propylene Glycol O Cocoate N PEG-55 Propylene Glycol O O Oleate N PEG-6 Propylene Glycol Caprylate/Caprate O = Old report N = New data Distributed for comment only -- do not cite or quote Search Strategy – PEG Propylene Glycol Derivatives SciFinder: INCI names and 1 CAS no. – The CAS no. had 0 results. The names had 1 set of results for CAS no 37231-60-0 90 hits OH-C-(CH2)16-CH3 O Culled for biological and toxicity studies – 29 hits. Removed patents – 7 hits. None useful. PubMed “PEG-25 Propylene Glycol Stearate” OR “PEG-75 Propylene Glycol Stearate” OR “PEG-120 Propylene Glycol Stearate” OR “PEG-10 Propylene Glycol” OR “PEG-8 Propylene Glycol Cocoate” OR “126645-98- 5” OR “PEG-55 Propylene Glycol Oleate” OR “PEG-6 Propylene Glycol Caprylate/Caprate” – 1 hit, the original safety assessment. ECHA INCI names and the CAS No and “Propylene Glycol Stearate” – no hits EU INCI names and the CAS No – No hits. SciFinder: Specific searches for “PEG-10 Propylene Glycol”; “PEG” and “Propylene Glycol”; “PEG Propylene Glycol”. Nothing useful. Structure search for “PEG-10 Propylene Glycol”. No hits. Distributed for comment only -- do not cite or quote Transcripts of PEG Propylene Glycol Derivatives June, 2016 Dr. Marks’ Team DR. MARKS: … And we're now at 13 of the hour. Do you want to move on to the propylene glycol esters? DR. SHANK: Sure. DR. HILL: Not really, but I think we should. DR. MARKS: I have -- not reopen. Do we add the PEG PG Caprylate/Caprate. That would -- to add it would be a no brainer. So, Tom, I hear -- DR. SHANK: Well, but if we add the one ingredient, do you have to open? MS. BECKER: Yes. DR. MARKS: Yes. MS. BECKER: But we're not reopening for cause. We're reopening for addition. DR. MARKS: Right. DR. SHANK: I say don't reopen. If you do, then you have change the conclusion to get rid of the caveat about damaged skin. DR. HILL: And also, let me just say that if we don't have any direct data on the PEG 10 propylene glycol, no reason to think that what little data we have on the esters necessarily informs the toxicology potential of the PEG 10 propylene glycol. And I calculate a molecular weight of 516 for the molecule when we don't have any physical chemical properties, anything about dermal absorption in the original report. I went back and looked. DR. SHANK: So are you saying open or not? DR. HILL: I'm suggesting let it alone. Don't reopen. DR. MARKS: Not open. DR. SHANK: Not open. DR. MARKS: Not open. Okay. That was quick. Okay. Since we have Bart here, should we go onto the priorities? Let's -- MS. BECKER: Sure. Not opening and not opening to add and not opening at all. Just making sure I understand. DR. MARKS: Correct. Yep. MS. BECKER: Okay. DR. MARKS: I'm going to move tomorrow that we do not reopen. DR. HILL: That would come up for re-review some years down, right? DR. MARKS: Mm-hmm. DR. HILL: Then could be looked at then. MR. ANSELL: Fifteen years. DR. MARKS: Okay. DR. HILL: Kick the can (inaudible). DR. MARKS: Thanks, Lillian. MS. BECKER: You're welcome. Dr. Belsito’s Team DR. BELSITO: … Yeah, okay, this is PEG-propylene glycol esters as used in cosmetics. So I thought we should reopen to add PEG-6 PGA Caprate [PEG PG Caprylate/Caprate] and also reopen just given the striking increase in abuse [use] of PEG-25 PG oleate but once having done that they're safe as used and I didn't need any other information. DR. LIEBLER: Right. I thought the read-across was adequate so safe as used.